Transforming Clinical Trials with Cutting-Edge ML
All Case Studies
Rescuing a Failed Trial: PhaseV Causal-ML Identifies Key Responders to Investigational Oral Insulin Treatment
Oramed’s Phase III oral insulin trial failed to meet its primary endpoint. PhaseV’s Causal-ML analysis identified responsive patient subgroups, leading to a targeted Phase III re-trial.
PhaseV’s Causal-ML identified responsive patient subgroups.
Accelerating SLE Trials: Early Derived Endpoint Reduces Sample Size & Enhances Trial Efficiency
Clinical trials in SLE face challenges due to disease heterogeneity and long follow-up periods. PhaseV’s ML analysis identified early response signals, enabling adaptive trial design and efficiency.
ML early endpoints optimized trials and improved success.
Optimizing a Phase III Trial for Sample Size
PhaseV optimized a biotech company's Phase III trial, reducing sample size while maintaining efficacy and meeting objectives through simulations.
Optimized trial design reduced sample size by 10-15%.
Enhancing Phase II Success with Subgroup Enrichment Strategy
PhaseV’s simulations identified an optimal subgroup enrichment strategy for a Phase II trial, improving statistical power and efficiency, leading to a more targeted study design.
Subgroup enrichment improved statistical power and efficiency.